title: The HEMO study - where do we go from here?
abstract: OBJECTIVE
  The HEMO study is a randomized clinical trial using a 2x2 factorial design to assign patients to a standard or high dose of dialysis and to a low flux or a high flux dialyzer. This study is the largest, most comprehensive, randomized clinical trial ever performed in the maintenance hemodialysis population. This review analyzes the results of the study and discusses how the HEMO study results affect efforts to lower morbidity and mortality in the hemodialysis population.
  
  
  RESULTS
  The primary outcome of the HEMO study was death from any cause. This outcome was not significantly influenced by treatment assignment for the dose of dialysis or for the flux of the dialysis membranes used. The main secondary outcomes also did not differ significantly in either the dose groups or the flux groups.
  
  
  CONCLUSIONS
  The results of the HEMO study support current clinical practice guidelines for the delivery of thrice-weekly dialysis, but the results do not support conventional attempts to lower the high morbidity and mortality in hemodialysis patients. Current efforts are being focused on increasing dialysis time and/or frequency, improving phosphate control, and lowering traditional and nontraditional risk factors for adverse cardiovascular events in this patient population.
authors.affiliation: Division of Nephrology and Renal Transplantation, Maine Medical Center, Portland 04102, USA. himmej@mmc.org
authors.forename: Jonathan
authors.initials: J
authors.lastname: Himmelfarb
mesh_terms: D006801:Humans; D007676:Kidney Failure, Chronic / Q000401:mortality / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic; D006435:Renal Dialysis / Q000009:adverse effects* / Q000379:methods*